GLP-1 users are defined as patients with an approved claim for at least one of the following GLP-1 medications in the prior 12 months: Mounjaro, Ozempic, Rybelsus, Saxenda, Wegovy, and Zepbound
It seems that as compared to a significant number of results confirming high efficacy of GLP-1RAs in rodent AD models, primarily in transgenic mice, very few clinical results of the beneficial effect of GLP-1RAs in patients with AD are presented
SBP reduction was mostly mediated by weight loss (7794%) in SURPASS-1, -2 and -3, while mechanisms independent from weight loss accounted for most of the tirzepatide benefit on SBP in SURPASS-4 and -5 (57 and 73%, respectively) [77]
Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd
Additionally, semaglutide has been shown to be safe for breastfeeding mothers, allowing them to prioritize their health without concerns for their babys safety